ClostraBio Fully Enrolls Placebo-Controlled Clinical Study of CLB101™, Expands Commercial Reach Through Distribution Partnership with Maypro
Published: January 12, 2026
Maypro Introduces CLB101™: Advancing Gut Health Through Clinical Research
Maypro is excited to announce the launch of a human clinical trial for CLB101™, the next-gen Anaerostipes caccae probiotic. Preclinical research has shown that CLB101™ uniquely stimulates butyrate production—an essential short-chain fatty acid for gut health—making it the only probiotic known to directly influence this process.
The placebo-controlled study has fully enrolled 48 adult participants for a four-week trial focused on evaluating safety and tolerability, while exploring CLB101™’s potential to support intestinal barrier integrity and overall gut wellness. Key endpoints include Gastrointestinal Symptom Rating Scale (GSRS) scores, gut permeability assessments, and biomarkers of inflammation and microbiome composition.
